Results 251 to 260 of about 206,533 (287)

HIV nucleoside reverse transcriptase inhibitors

European Journal of Medicinal Chemistry, 2022
More than 40 years into the pandemic, HIV remains a global burden and as of now, there is no cure in sight. Fortunately, highly active antiretroviral therapy (HAART) has been developed to manage and suppress HIV infection. Combinations of two to three drugs targeting key viral proteins, including compounds inhibiting HIV reverse transcriptase (RT ...
Franck, Amblard, Dharmeshkumar, Patel, Eleftherios, Michailidis, Steven J, Coats, Mahesh, Kasthuri, Nicolas, Biteau, Zahira, Tber, Maryam, Ehteshami, Raymond F, Schinazi   +8 more
openaire   +2 more sources

Nonnucleoside reverse transcriptase inhibitors

Drugs of the Future, 2000
The non-nucleoside reverse transcriptase inhibitors (NNRTIs) directly inhibit the HIV-1 reverse transcriptase (RT) by binding in a reversible and non-competitive manner to the enzyme. The currently available NNRTIs are nevirapine, delavirdine, and efavirenz; other compounds are under evaluation.
null Hajos, G., null Riedl, Z., null Molnar, J., null Szabo, D.   +3 more
openaire   +3 more sources

HIV-1 reverse transcriptase inhibitors

Applied Microbiology and Biotechnology, 2007
Reverse transcriptase (RT) is one of the three enzymes encoded by the human immunodeficiency virus type 1 (HIV-1), the etiological agent of AIDS. Together with protease inhibitors, drugs inhibiting the RNA- and DNA-dependant DNA polymerase activity of RT are the major components of highly active antiretroviral therapy (HAART), which has dramatically ...
El Safadi, Yazan, Vivet-Boudou, Valérie, Marquet, Roland   +2 more
openaire   +3 more sources

Hepatotoxicity of Nucleoside Reverse Transcriptase Inhibitors

Seminars in Liver Disease, 2003
Hepatotoxicity is an adverse effect of all available classes of antiretrovirals, including nucleoside reverse transcriptase inhibitors (NRTI). A syndrome of hepatic steatosis and lactic acidosis has been recognized as a rare, potentially fatal complication since the advent of NRTI monotherapy in the early 1990s.
Valentina, Montessori, Marianne, Harris, Julio S G, Montaner   +2 more
openaire   +2 more sources

New Reverse Transcriptase Inhibitors

1999
Reverse transcriptase inhibitors used in the treatment of HIV-1 infection include the nucleoside analogues zidovudine, didanosine, zalcitabine, lamivudine and stavudine. More recently a number of other classes of reverse transcriptase inhibitors have been discovered, and are in various phases of clinical trial. This chapter will focus on the nucleoside
openaire   +2 more sources

Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial

AIDS, 2009
The use of nonnucleoside reverse transcriptase inhibitor (NNRTI) + protease inhibitor regimen for the treatment of antiretroviral-naive patients was less successful than classical nucleoside reverse transcriptase inhibitor (NRTI) based regimen and associated with more resistance for protease inhibitors and NNRTIs. The selection for NNRTI resistance was
Cathia, Soulié, Lambert, Assoumou, Jade, Ghosn, Claudine, Duvivier, Gilles, Peytavin, Zaina, Ait-Arkoub, Jean-Michel, Molina, Dominique, Costagliola, Christine, Katlama, Vincent, Calvez, Anne-Geneviève, Marcelin   +10 more
openaire   +2 more sources

Inhibitors of HIV‐1 Reverse Transcriptase

2008
Publisher Summary With the identification of human immunodeficiency virus (HIV)‐1 as the infectious agent leading to acquired immune deficiency syndrome (AIDS), the viral reverse transcriptase (RT) has been a primary focus for drug discovery and development. Currently, two classes of RT inhibitors are used clinically. Nucleoside reverse transcriptase
Tatiana, Ilina, Michael A, Parniak
openaire   +2 more sources

Novel HIV-1 reverse transcriptase inhibitors

Virus Research, 2008
HIV-1 reverse transcriptase (RT) was the first viral enzyme to be targeted by anti-HIV drugs. Despite 20 years of experience with RT inhibitors, new ways to inhibit this target and address viral resistance continue to emerge. In both licensed RT inhibitor classes, nucleosides (NRTIs) and non-nucleosides (NNRTIs), compounds with better resistance ...
openaire   +2 more sources

Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs)

2013
HIV is a retrovirus; the retroviral life cycle is characterized by two specific steps: (1) the conversion of the single-stranded RNA genome found in the virion into double-stranded DNA by the viral enzyme reverse transcriptase (RT) and (2) the subsequent insertion of this DNA copy into the host genome by the viral enzyme integrase.
Kalyan Das, Eddy Arnold, Stephen H. Hughes   +2 more
openaire   +1 more source

[Reverse transcriptase inhibitors, protease inhibitors].

Nihon rinsho. Japanese journal of clinical medicine, 2012
These are six different classes of antiretroviral drugs that are nucleoside/nucleotide reverse transcriptase inhibitors(NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors, CCR5 inhibitors and integrase inhibitors. NRTIs are thought as backbone of HAART(highly active antiretroviral therapy) and
openaire   +1 more source